Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one case

Since chylothorax is uncommon and has multiple causes, its best treatment choice is not clear. Recent reports show that octreotide is useful in the treatment of chlylothorax secondary to cancer or caused by surgical procedures. We report a 21 years old male with a chylothorax secondary to a non Hodgkin lymphoma. Treatment with octreotide changed the color and triglyceride content of pleural effusion. Serum albumin and proteins increased and the effusion subsided after the second cycle of chemotherapy with CHOP. Thus octreotide was discontinued on the 27th day of therapy and pleural drainages were whithdrawn. He was discharged in good conditions, 38 days after admission (Rev Méd Chile 2005; 133: 1473-76)

Saved in:
Bibliographic Details
Main Authors: Lesina B,Blaz, Aburto B,María
Format: Digital revista
Language:Spanish / Castilian
Published: Sociedad Médica de Santiago 2005
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005001200009
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-98872005001200009
record_format ojs
spelling oai:scielo:S0034-988720050012000092006-01-27Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one caseLesina B,BlazAburto B,MaríaSince chylothorax is uncommon and has multiple causes, its best treatment choice is not clear. Recent reports show that octreotide is useful in the treatment of chlylothorax secondary to cancer or caused by surgical procedures. We report a 21 years old male with a chylothorax secondary to a non Hodgkin lymphoma. Treatment with octreotide changed the color and triglyceride content of pleural effusion. Serum albumin and proteins increased and the effusion subsided after the second cycle of chemotherapy with CHOP. Thus octreotide was discontinued on the 27th day of therapy and pleural drainages were whithdrawn. He was discharged in good conditions, 38 days after admission (Rev Méd Chile 2005; 133: 1473-76)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.133 n.12 20052005-12-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005001200009es10.4067/S0034-98872005001200009
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language Spanish / Castilian
format Digital
author Lesina B,Blaz
Aburto B,María
spellingShingle Lesina B,Blaz
Aburto B,María
Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one case
author_facet Lesina B,Blaz
Aburto B,María
author_sort Lesina B,Blaz
title Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one case
title_short Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one case
title_full Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one case
title_fullStr Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one case
title_full_unstemmed Uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: Report of one case
title_sort uso de octreotide (análogo de somatostatina) en un caso de quilotórax bilateral secundario a linfoma: report of one case
description Since chylothorax is uncommon and has multiple causes, its best treatment choice is not clear. Recent reports show that octreotide is useful in the treatment of chlylothorax secondary to cancer or caused by surgical procedures. We report a 21 years old male with a chylothorax secondary to a non Hodgkin lymphoma. Treatment with octreotide changed the color and triglyceride content of pleural effusion. Serum albumin and proteins increased and the effusion subsided after the second cycle of chemotherapy with CHOP. Thus octreotide was discontinued on the 27th day of therapy and pleural drainages were whithdrawn. He was discharged in good conditions, 38 days after admission (Rev Méd Chile 2005; 133: 1473-76)
publisher Sociedad Médica de Santiago
publishDate 2005
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005001200009
work_keys_str_mv AT lesinabblaz usodeoctreotideanalogodesomatostatinaenuncasodequilotoraxbilateralsecundarioalinfomareportofonecase
AT aburtobmaria usodeoctreotideanalogodesomatostatinaenuncasodequilotoraxbilateralsecundarioalinfomareportofonecase
_version_ 1755988178324422656